Krystal Biotech (KRYS) EVP Laurent Goux details options, RSUs and stock

Rhea-AI Filing Summary

Krystal Biotech EVP Laurent Goux has filed an initial ownership report showing equity awards and stock holdings in Krystal Biotech, Inc. The Form 3 lists several grants of stock options and restricted stock units, plus common shares, all held directly as of March 1, 2026.

Stock option positions include grants covering 9,050, 7,449, 2,367, 4,750, 2,750 and 19,000 shares of common stock. Restricted stock unit awards include 3,628, 891 and 674 units, and he directly holds 919 shares of common stock.

The footnotes state that multiple option and RSU grants vest in four equal annual installments on the first through fourth anniversaries of their grant dates in 2023, 2024, 2025 and 2026, subject to his continued service, and note that one stock option grant for 19,000 shares is fully vested.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Goux Laurent Louis Jean

(Last) (First) (Middle)

C/O KRYSTAL BIOTECH, INC.

2100 WHARTON STREET, SUITE 701

(Street)

PITTSBURGH PA 15203

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
03/01/2026

3. Issuer Name and Ticker or Trading Symbol
Krystal Biotech, Inc. [ KRYS ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Head of International

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	919	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(1)	02/26/2036	Common Stock	9,050	$275.64	D
Restricted Stock Units	(2)	(2)	Common Stock	3,628(3)	(4)	D
Stock Option (Right to Buy)	(5)	02/27/2035	Common Stock	7,449	$179.25	D
Restricted Stock Units	(6)	(6)	Common Stock	891(3)	(4)	D
Stock Option (Right to Buy)	(7)	02/27/2034	Common Stock	2,367	$159.47	D
Restricted Stock Units	(8)	(8)	Common Stock	674(3)	(4)	D
Stock Option (Right to Buy)	(9)	02/27/2033	Common Stock	4,750	$81.91	D
Stock Option (Right to Buy)	(10)	02/27/2032	Common Stock	2,750	$63.55	D
Stock Option (Right to Buy)	(10)	09/29/2031	Common Stock	19,000	$52.21	D

Explanation of Responses:

1. The stock option was granted on February 27, 2026, and vests in four equal annual installments on each of the first, second, third, and fourth anniversaries of the grant date, subject to the Reporting Person's continued service through each applicable vesting date.

2. The restricted stock units ("RSUs") vest in four equal annual installments with the first installment vesting on February 27, 2027.

3. The number of RSUs in this column represents the number of shares of common stock the Reporting Person will receive assuming the Reporting Person's continued service to the Company on all applicable vesting dates.

4. Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date.

5. The stock option was granted on February 28, 2025, and vested or will vest in four equal annual installments on each of the first, second, third, and fourth anniversaries of the grant date, subject to the Reporting Person's continued service through each applicable vesting date.

6. The RSUs vested or will vest in four equal annual installments on each of the first, second, third, and fourth anniversaries of the grant date, February 28, 2025, subject to the Reporting Person's continued service through each applicable vesting date.

7. The stock option was granted on February 29, 2024, and vested or will vest in four equal annual installments on each of the first, second, third, and fourth anniversaries of the grant date, subject to the Reporting Person's continued service through each applicable vesting date.

8. The RSUs vested or will vest in four equal annual installments on each of the first, second, third, and fourth anniversaries of the grant date, February 29, 2024, subject to the Reporting Person's continued service through each applicable vesting date.

9. The stock option was granted on February 28, 2023, and vested or will vest in four equal annual installments on each of the first, second, third, and fourth anniversaries of the grant date, subject to the Reporting Person's continued service through each applicable vesting date.

10. The stock option is fully vested.

Remarks:

Exhibit 24.1 Power of Attorney

	/s/ Laurent Goux	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does Krystal Biotech (KRYS) EVP Laurent Goux report on this Form 3?

Laurent Goux reports his initial beneficial ownership in Krystal Biotech, Inc., including multiple stock option and restricted stock unit grants plus common shares. These holdings reflect his equity-based compensation as EVP, Head of International, all held directly as of March 1, 2026.

How many Krystal Biotech (KRYS) stock options does Laurent Goux hold?

The Form 3 lists several stock option grants for 9,050, 7,449, 2,367, 4,750, 2,750 and 19,000 shares. Each grant represents the right to buy Krystal Biotech common stock, with vesting tied to specific grant dates and continued service conditions described in the footnotes.

What restricted stock units in Krystal Biotech (KRYS) does Laurent Goux beneficially own?

Laurent Goux holds restricted stock unit awards of 3,628, 891 and 674 units. Each RSU represents a contingent right to receive one share of Krystal Biotech common stock, vesting in four equal annual installments if he remains in service through the applicable vesting dates.

How many Krystal Biotech (KRYS) common shares does Laurent Goux directly own?

The filing shows that Laurent Goux directly owns 919 shares of Krystal Biotech common stock. This ownership is in addition to his stock options and restricted stock units, which may convert into additional shares over time as vesting conditions are satisfied.

What are the vesting terms for Laurent Goux’s Krystal Biotech (KRYS) equity awards?

Several stock option and RSU grants vest in four equal annual installments on the first through fourth anniversaries of grant dates in 2023, 2024, 2025 and 2026. Vesting is conditioned on Laurent Goux’s continued service with Krystal Biotech on each applicable vesting date.

Is any of Laurent Goux’s Krystal Biotech (KRYS) stock fully vested?

Yes. One stock option grant covering 19,000 shares of Krystal Biotech common stock is described as fully vested. Other option and restricted stock unit grants vest over time in equal annual installments, contingent on his continued service with the company.